Eledon Pharmaceuticals Inc
eledon.comEledon Pharmaceuticals Inc (NASDAQ: ELDN) is a clinical-stage biopharmaceutical company developing treatments for amyotrophic lateral sclerosis (ALS) and related neuroinflammatory diseases. The company generates no product revenue as of the 10-K filed March 19, 2026; it funds operations through equity issuances, including common stock and pre-funded warrants under securities purchase agreements and underwritten offerings. Its lead candidate, tegoprubart, is a CD40L-blocking antibody designed to inhibit neuroinflammatory pathways believed to drive ALS progression. In preclinical SOD1 mouse models, tegoprubart's mechanism demonstrated prolonged survival, reduced macrophage infiltration into skeletal muscle, improved neuromuscular junction occupancy, and improved motor neuron survival. The company has no approved products, no marketing or sales force, and no commercial revenue as of the filing date. CEO is David-Alexandre C. Gros, M.D., and President is Steven Perrin, with Keith A. Katkin serving as Chairman of the Board, as of March 19, 2026.
Products & Services
Tegoprubart: a clinical-stage anti-CD40L monoclonal antibody targeting neuroinflammatory pathways in ALS. No approved or commercialized products as of March 19, 2026.
Revenue Model
No product revenue as of the 10-K filed March 19, 2026. Operations are funded through equity capital raises, including securities purchase agreements and underwritten public offerings of common stock and pre-funded warrants.
Customers & Markets
Target end market is ALS patients. No commercial customers as of the filing date. Potential future customers would be ALS patients and prescribing physicians, subject to regulatory approval.
Geographic Exposure
Primarily U.S.-regulated operations, with reference to international regulatory challenges in the 10-K filed March 19, 2026. No specific geographic revenue breakdown disclosed.
Financial Snapshot
Loading...
